Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies
- 14 August 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 18 (6), 751-759
- https://doi.org/10.1007/s00520-009-0711-6
Abstract
Probiotics are expected to be effective in prophylaxis of infection in cancer patient, since infections in neutropenics are mainly caused by endogenous flora through the intestinal mucosa. However, the experience with the use of probiotics in immunocompromised patients is limited, and precise fecal bacteria analysis has not been reported. The aim of the study was to evaluate the effects of the enteral administration of the probiotic, Bifidobacterium breve strain Yakult, on its ability to prevent infection, fecal micro flora, and intestinal environments in cancer patients on chemotherapy. A placebo-controlled trial was performed at Juntendo University Hospital. Patients with malignancies admitted for chemotherapy (n = 42) were randomized into two groups receiving probiotic or placebo. The effects on infectious complications, natural killer cells, fecal micro flora, fecal organic acid concentrations, and fecal pH were studied. The frequency of fever and the use of intravenous antibiotics were lower in the probiotic group than the placebo group. The probiotic administration enhanced the habitation of anaerobes. Disruption of the intestinal microbiota after chemotherapy such as the increase in the population levels of Enterobacteriaceae was observed at more pronounced manner in the placebo group in comparison to the probiotic group. The concentrations of total organic acids were maintained most of the time at the normal level, which constantly maintained the pH below 7.0 only in the probiotic group. These data, although based on a limited number of patients and samples, suggest that administration of B. breve strain Yakult could be an effective approach for achieving clinical benefits in immunocompromised hosts by improving their intestinal environments.Keywords
This publication has 33 references indexed in Scilit:
- Immunomodulatory effects of probiotics in different stages of lifeBritish Journal of Nutrition, 2007
- Essential Roles of Monocytes in Stimulating Human Peripheral Blood Mononuclear Cells with Lactobacillus casei To Produce Cytokines and Augment Natural Killer Cell ActivityClinical and Vaccine Immunology, 2006
- Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II studySupportive Care in Cancer, 2005
- Probiotic Bifidobacteria Protect Mice from Lethal Infection with Shiga Toxin-Producing Escherichia coli O157:H7Infection and Immunity, 2004
- Antibacterial Effect of Fermented Milk ContainingBifidobacterium breve, Bifidobacterium bifidum and Lactobacillus acidophilusagainst IndigenousEscherichia coliInfection in MiceMicrobial Ecology in Health & Disease, 2001
- Correlation between water‐holding capacity of different types of cellulose in vitro and gastrointestinal retention time in vivo of ratsJournal of the Science of Food and Agriculture, 1992
- A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patientsDiagnostic Microbiology and Infectious Disease, 1989
- The Effects of Bifidobacterium breve Administration on Campylobacter EnteritisPediatrics International, 1987
- Clinical effects of bifidobacterium preparations on pediatric intractable diarrhea.The Keio Journal of Medicine, 1987
- Selective Agar Medium for Counting Viable Cells of Bifidobacteria in Fermented MilkFood Hygiene and Safety Science (Shokuhin Eiseigaku Zasshi), 1986